NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS)(DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today it has closed on a private equity investment in the Company totaling approximately $13.5 million. The financing, which is a continuation of the investment announced on February 14, 2007, included as investors the Technion-Israel Institute of Technology and inventors who collaborated on the technology and whose patents were acquired by Pluristem.
